University of Chicago Medicine

Comprehensive Cancer Center

Chicago, IL

Website

(888) 803-1766 Refer Patient

Filters

Personalize My Search

Sorting 8 by

Accepting patients

ACCESS

HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide (ACCESS)

Learn more

Allogeneic Stem Cell Transplant
Pre-Transplant
Phase 2

Accepting patients

Venetoclax in Combination With ASTX727

Venetoclax in Combination With ASTX727, an All-ORal Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN With Excess Blasts (VICTORY-MDS/MPN): A Randomized, Phase 2 Trial

Learn more

BCL-2 Inhibitor
Hypomethylating Agents (HMA)
Phase 2

Get personalized results in 60 seconds

All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.

Help me find trials

Accepting patients

Intensity Modulated Total Marrow Irradiation

A Phase I Study of Intensity Modulated Total Marrow Irradiation (IMTMI) in Addition to Fludarabine/Melphalan Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies

Learn more

Allogeneic Stem Cell Transplant
Radiation
Phase 1

Accepting patients

Mismatched Related vs. Matched Unrelated Donor

A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) Versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) With Acute Leukemia or Myelodysplastic Syndrome (MDS)

Learn more